Fig. 7From: Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapyT1-weighted MRI in May of 2017 demonstrating ongoing, subtotal tumor responseBack to article page